Clinical Trials List
2025-03-01 - 2032-12-31
Phase III
Recruiting5
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/13
Investigators and Locations
Co-Principal Investigator
- 黃怡菁 無
- Zhu-Jun Loh 無
- Kuo-Ting Lee Division of General Surgery
- Jui-Hung Tsai 無
- Chun-Hui Lee Division of Hematology & Oncology
- 楊舜如 無
- Shang-Hung Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HSIN-CHEN LIN Division of Hematology & Oncology
- 楊捷儒 無
- Kuan-Der Lee Division of Hematology & Oncology
- 劉佳樺 無
- 王國鐘 Division of General Surgery
- 林慈恩 Division of General Surgery
- 楊陽生 無
- ZHENG-WEI ZHOU 無
- Huey-En Tzeng Division of Hematology & Oncology
- I-Chen Tsai 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈士哲 Division of General Surgery
- Yung-Chang Lin Division of Hematology & Oncology
- Chi-Chang Yu Division of General Surgery
- 阮昱翔 Division of Radiology
- Wen-Chi Shen Division of Hematology & Oncology
- Wen-Ling Kuo Division of General Surgery
- Chan-Keng Yang Division of Hematology & Oncology
- 周旭桓 Division of General Surgery
- Mengting Peng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李佳真 Division of General Internal Medicine
- 張端瑩 Division of Hematology & Oncology
- 楊明翰
- 林柏翰 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- 陳怡君
- 林季宏 Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 羅喬
- MING-YANG WANG Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- 黃柏翔
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
28 participants
-
Global
1000 participants
